Related references
Note: Only part of the references are listed.Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort
Diana M. Negoescu et al.
INFLAMMATORY BOWEL DISEASES (2020)
Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease
David J. Gibson et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial
Xavier Roblin et al.
GUT (2020)
Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial
Manar Matar et al.
INFLAMMATORY BOWEL DISEASES (2020)
New treatment options for inflammatory bowel diseases
Bram Verstockt et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis
Konstantinos Papamichael et al.
JOURNAL OF CROHNS & COLITIS (2017)
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases
N. Mitrev et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial
H. Nakase et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease
M. G. Ward et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF- naive Crohn's disease
N. Narula et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
The Steady-State Pharmacokinetics of Adalimumab: Do We Need to Drink From the Trough?
Michael J. Stewart et al.
GASTROENTEROLOGY (2016)
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial
Takayuki Matsumoto et al.
JOURNAL OF CROHNS & COLITIS (2016)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
L. Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Pharmacokinetics of adalimumab in Crohn's disease
David Ternant et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
Reena Khanna et al.
LANCET (2015)
Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
Y. Mazor et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
Xavier Roblin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients
Charlotte P. Peters et al.
JOURNAL OF CROHNS & COLITIS (2014)
Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment
Hirotsugu Imaeda et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study
Stephane Paul et al.
INFLAMMATORY BOWEL DISEASES (2013)
Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
C. Reenaers et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
MECHANISMS OF DISEASE Inflammatory Bowel Disease
Clara Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inflammatory bowel disease
DK Podolsky
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
